Pharmacotherapy for Retinopathy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 February 2025 | Viewed by 2182
Special Issue Editor
Special Issue Information
Dear Colleagues,
The mechanisms underlying retinopathy of prematurity (ROP) development, progression and recurrence have not been fully elucidated. As with most pathologic proliferative retinal vascular diseases, the blockage of vascular endothelial growth factor (VEGF) by an intravitreal injection has become the mainstay of treatment. Several anti-VEGF agents are in use for aggressive posterior ROP, and trials have indicated non-inferiority to laser photocoagulation. Although anatomic and functional outcomes may be improved with pharmacotherapy, recurrences are common, unpredictable and may lead to blindness. Furthermore, the disease presents lifelong risks of visual loss.
In furtherance of advancing ROP treatment, we wish to better understand the role of VEGF blockade, the precise molecular switching mechanisms at play, inducible-factor interactions, nutrition and tissue-constitutive factors that play a role in the complex formation of pathologic neovascularization in ROP.
Dr. Eric Shrier
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retinopathy of prematurity
- ROP
- anti-VEGF
- HIF
- pathologic neovascularization
- OIR
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
